Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
Find the perfect cards to make your season’s greetings go even further. Every pack purchased will help fund vital research and support for people living with type 1 diabetes.
Researchers need your help. By taking part in research studies and clinical trials, you will help them make progress to improve lives and find a cure for type 1 diabetes.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Your donation helps support people living with type 1 diabetes and funds the best treatment and cure research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > Tegoprubart trial explores islet transplants for T1D and kidney disease
The study will explore whether this experimental treatment could help protect transplanted insulin-producing cells while reducing some of the risks associated with conventional immunosuppressant medicines. These medicines stop your body from attacking transplanted cells, and can also be known as anti-rejection drugs.
The research could provide important insights into a potential barrier to islet transplantation for people with T1D and kidney disease. However, the trial is at an early stage, and further research will be needed to establish whether the approach is safe and effective.
Islet transplantation involves transferring clusters of cells, including insulin-producing cells, from a donor pancreas into a person with T1D. The aim is to help the recipient produce their own insulin and improve blood glucose management.
After transplantation, recipients will need to take immunosuppressant or anti-rejection medicines. However, some of these medicines can damage the kidneys, removing transplantation as an option for people who already have kidney disease.
The new US trial will investigate whether tegoprubart could help address this challenge. Researchers plan to enrol up to 10 participants, assessing outcomes over the first year after transplantation.
The team will examine measures including whether participants can stop taking external insulin, achieve an HbA1c below 7% and avoid severe hypoglycaemia, using continuous glucose monitoring to help assess glucose outcomes.
Tegoprubart is an experimental treatment designed to help prevent the immune system from rejecting transplanted cells. It works by blocking certain cells in the immune system that would normally destroy the newly transplanted cells. It has been engineered to work in a very particular way, which reduces harmful side effects.
Researchers are investigating whether it could offer an alternative to conventional immunosuppressant medicines, potentially helping transplanted islets survive while reducing some of the associated risks.
The treatment is also being studied in islet transplantations involving people with T1D without the specific focus on kidney disease. In a separate study involving 12 participants, encouraging results have been reported, including all 12 participants no longer needing external insulin at the latest reported update.
Kidney disease can be a serious complication of T1D, and it can limit the treatment options available to some people. Exploring ways to make islet transplantation safer for people with kidney problems could help researchers address an important unmet need.
There is still much to learn. The new trial is small and at an early stage, so its results will be important in determining whether tegoprubart is safe and effective for this group and whether larger studies are justified.
Breakthrough T1D have funded this trial via the T1D fund and through a direct grant of $8.5 million given to Eledon Pharmaceuticals for this research.
Esther Latres, Ph.D., Breakthrough T1D Senior Vice President of Research in the US said:
“Advancing promising islet cell research that is a next step toward durable and scalable cures for type 1 diabetes is a key priority for Breakthrough T1D, We’re proud to support this trial that expands cell therapy research and access to people living with T1D and chronic kidney disease for the first time.”
Find out how early detection works, why it matters, and how you can access screening for yourself, your child or someone you care for.
Dealing with type 1 every day can have an emotional impact, whether you’re newly diagnosed or have been living with type 1 for some time.
Find out about our research to find cures for T1D and make everyday life better for those who face it.
A new international position statement says people with diabetes should often be able to keep using continuous glucose monitors, insulin pumps and hybrid closed loop systems during a hospital stay, as long as it is safe and appropriate.
We look at a new feature coming to the CamAPS FX app, which will allow users to remove the need to count carbohydrates before a meal.
In draft guidance published today, NICE recommends that anyone with type 1 diabetes who is pregnant or planning a pregnancy should be offered pregnancy-specific HCL technology.
Discussing the main themes from this year's Advanced Technologies & Treatments for Diabetes conference – early detection, cellular cures and disease-modifying therapies.
Researchers from John Hopkins University, USA, partially funded by Breakthrough T1D, have developed an experimental treatment that protects the insulin-producing cells from inflammatory damage, allowing them to survive for longer in animal models.
Would you like to visit the website of our {{ affiliate_country }} affiliate to complete your action?
